PolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056
Posted by: admin in Polymer NewsPolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056 RADNOR, Pa.—-PolyMedix, Inc. , an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has scheduled a webcast for Wednesday, June 9 at 4:00 PM Eastern Time. Read more on Business Wire via Yahoo!…. Click Here to Read More






Entries (RSS)